Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials [1][3] - The company holds over 270 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [3] Company Presentation - The CEO, Pete O'Heeron, will present at the Bio-Europe 2025 conference from November 3-5, 2025, in Vienna, Austria [1] - FibroBiologics is scheduled to deliver a company presentation on November 4 at 4:15 p.m. CET and will be available for one-on-one investor meetings during the event [2] Company Overview - FibroBiologics is based in Houston and represents the next generation of medical advancement in cell therapy and tissue regeneration [3] - The company is actively developing a pipeline of treatments aimed at chronic diseases, leveraging its extensive patent portfolio [3]
FibroBiologics to Present at Bio-Europe 2025